Naratuximab (CAS: 1622327-39-2)
Naratuximab is a humanized monoclonal antibody targeting CD37, expressed on B cells. It is used in developing antibody-drug conjugates (ADCs) to deliver cytotoxic agents directly to B cells, improving treatment for B-cell malignancies.
Key Features:
- Target Specificity: Binds to CD37 on B cells.
- Mechanism of Action: Used to create ADCs that deliver cytotoxic agents to B cells.
- Therapeutic Potential: Investigated for treating B-cell cancers like non-Hodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL).
Applications:
- Cancer Research: Develops ADCs for targeted B-cell cancer therapies.
- ADC Development: Naratuximab can be used to create Naratuximab emtansine (IMGN529), an ADC combining DM1 with the anti-CD37 antibody, enhancing anti-tumor effects by combining proapoptotic and cytotoxic activities.
Handling and Storage:
- Formulation: Available as a research-grade biosimilar antibody.
- Storage: Store at -20°C in a dry, light-protected environment.
- Precautions: Use personal protective equipment and handle in a well-ventilated area.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
